fda decision on compounded tirzepatide Some patients now turn to copycat versions of popular weight loss drugs Compounded Tirzepatide: Legal & Safe

There is interest in GLP-1 agonists and their ability to either reduce atherosclerotic plaque burden or the potential for plaque disruption- recognized as a proximate cause of arterial thrombotic events

Alternatively, some patients transition to the Microdose GLP-1 Protocol ($129/mo flat) to sustain appetite control at a lower intensity

Without enough glutathione, the recovery process slows down significantly as your body struggles to clear toxic metabolic byproducts

Cell Metabolism, 22(1), 31-53

doi: 10.1016/j.joca.2023.05.014 137

Understanding both sides will help you have an informed conversation with your healthcare provider